Dynavax to Show Positive Flu Drug Data
Thursday October 19, 6:10 pm ET
Dynavax Technologies to Present Positive Preclinical Data on Flu Vaccine
BERKELEY, Calif. (AP) -- Drug developer Dynavax Technologies said it will present preclinical data Friday showing its flu vaccine candidate can improve the effectiveness of other flu vaccines.
The data will be presented at the Second International Conference on Influenza Vaccines for the World, in Vienna. The data from a study on involving mice and primate models showed its flu vaccine, when given with other standard vaccines, increases the immunogenicity, or the immune response, of the standard vaccines. That means it would allow for the reduction of dosages in standard vaccine and provide extra layers of protection that aren't strain-dependent.
The study was funded in part with $3 million from the National Institutes of Health as part of a grant to develop a pandemic flu vaccine. Dynavax is developing its vaccine based on a TLR9 agonist.
Shares of Dynavax fell 42 cents, or 6.4 percent, to close at $6.13 on the Nasdaq, but rebounded 37 cents, or 6 percent, to $6.50 in aftermarket activity. |
